BIOMAT Database Logo BIOMAT Database Logo

Phase II trial of topotecan in advanced or metastatic adenocarcinoma of the pancreas. 1996

R M Scher, and R Kosierowski, and C Lusch, and R Alexander, and S Fox, and I Redei, and F Green, and B Raskay, and K Amfoh, and P F Engstrom, and P J O'Dwyer
Fox Chase Cancer Center, Philadelphia, PA 19111, USA.

OBJECTIVE A phase II trial of topotecan, an inhibitor of topoisomerase I, was conducted in patients with advanced or metastatic adenocarcinoma of the pancreas to determine the activity and toxicity of topotecan. METHODS 35 patients, previously untreated with chemotherapy, received topotecan 1.5 mg/m2/d for five days intravenously and repeated every 21 days. Patients were assessed for response after 3 cycles. Those with either clinical response or stable disease received additional cycles of the drug until toxicity developed or disease progression occurred. RESULTS Among 30 patients evaluable for response there were no complete responses and 3 partial responses (10%) for a total response rate of 10% (95% confidence interval = 0-20.6%). Stable disease for at least eight weeks was seen in 11 patients (36%). Median survival was 19 weeks (95% confidence interval 11 to 26 weeks). Therapy was generally well tolerated, with reversible granulocytopenia being the most common toxicity. CONCLUSIONS Topotecan given on a 5 day, short infusion schedule, demonstrated limited activity in pancreatic carcinoma with minimal toxicity. Further exploration of topotecan in pancreatic carcinoma using different dosing schedules is warranted.

UI MeSH Term Description Entries
D007262 Infusions, Intravenous The long-term (minutes to hours) administration of a fluid into the vein through venipuncture, either by letting the fluid flow by gravity or by pumping it. Drip Infusions,Intravenous Drip,Intravenous Infusions,Drip Infusion,Drip, Intravenous,Infusion, Drip,Infusion, Intravenous,Infusions, Drip,Intravenous Infusion
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009362 Neoplasm Metastasis The transfer of a neoplasm from one organ or part of the body to another remote from the primary site. Metastase,Metastasis,Metastases, Neoplasm,Metastasis, Neoplasm,Neoplasm Metastases,Metastases
D010190 Pancreatic Neoplasms Tumors or cancer of the PANCREAS. Depending on the types of ISLET CELLS present in the tumors, various hormones can be secreted: GLUCAGON from PANCREATIC ALPHA CELLS; INSULIN from PANCREATIC BETA CELLS; and SOMATOSTATIN from the SOMATOSTATIN-SECRETING CELLS. Most are malignant except the insulin-producing tumors (INSULINOMA). Cancer of Pancreas,Pancreatic Cancer,Cancer of the Pancreas,Neoplasms, Pancreatic,Pancreas Cancer,Pancreas Neoplasms,Pancreatic Acinar Carcinoma,Pancreatic Carcinoma,Acinar Carcinoma, Pancreatic,Acinar Carcinomas, Pancreatic,Cancer, Pancreas,Cancer, Pancreatic,Cancers, Pancreas,Cancers, Pancreatic,Carcinoma, Pancreatic,Carcinoma, Pancreatic Acinar,Carcinomas, Pancreatic,Carcinomas, Pancreatic Acinar,Neoplasm, Pancreas,Neoplasm, Pancreatic,Neoplasms, Pancreas,Pancreas Cancers,Pancreas Neoplasm,Pancreatic Acinar Carcinomas,Pancreatic Cancers,Pancreatic Carcinomas,Pancreatic Neoplasm
D002166 Camptothecin An alkaloid isolated from the stem wood of the Chinese tree, Camptotheca acuminata. This compound selectively inhibits the nuclear enzyme DNA TOPOISOMERASES, TYPE I. Several semisynthetic analogs of camptothecin have demonstrated antitumor activity. Camptothecine
D004334 Drug Administration Schedule Time schedule for administration of a drug in order to achieve optimum effectiveness and convenience. Administration Schedule, Drug,Administration Schedules, Drug,Drug Administration Schedules,Schedule, Drug Administration,Schedules, Drug Administration
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000230 Adenocarcinoma A malignant epithelial tumor with a glandular organization. Adenocarcinoma, Basal Cell,Adenocarcinoma, Granular Cell,Adenocarcinoma, Oxyphilic,Adenocarcinoma, Tubular,Adenoma, Malignant,Carcinoma, Cribriform,Carcinoma, Granular Cell,Carcinoma, Tubular,Adenocarcinomas,Adenocarcinomas, Basal Cell,Adenocarcinomas, Granular Cell,Adenocarcinomas, Oxyphilic,Adenocarcinomas, Tubular,Adenomas, Malignant,Basal Cell Adenocarcinoma,Basal Cell Adenocarcinomas,Carcinomas, Cribriform,Carcinomas, Granular Cell,Carcinomas, Tubular,Cribriform Carcinoma,Cribriform Carcinomas,Granular Cell Adenocarcinoma,Granular Cell Adenocarcinomas,Granular Cell Carcinoma,Granular Cell Carcinomas,Malignant Adenoma,Malignant Adenomas,Oxyphilic Adenocarcinoma,Oxyphilic Adenocarcinomas,Tubular Adenocarcinoma,Tubular Adenocarcinomas,Tubular Carcinoma,Tubular Carcinomas

Related Publications

R M Scher, and R Kosierowski, and C Lusch, and R Alexander, and S Fox, and I Redei, and F Green, and B Raskay, and K Amfoh, and P F Engstrom, and P J O'Dwyer
A phase II trial of perifosine in locally advanced, unresectable, or metastatic pancreatic adenocarcinoma.
February 2007, American journal of clinical oncology,
R M Scher, and R Kosierowski, and C Lusch, and R Alexander, and S Fox, and I Redei, and F Green, and B Raskay, and K Amfoh, and P F Engstrom, and P J O'Dwyer
Phase II trial of menogarol in the treatment of advanced adenocarcinoma of the pancreas.
April 1988, American journal of clinical oncology,
R M Scher, and R Kosierowski, and C Lusch, and R Alexander, and S Fox, and I Redei, and F Green, and B Raskay, and K Amfoh, and P F Engstrom, and P J O'Dwyer
Front-line paclitaxel and topotecan chemotherapy in advanced or metastatic non-small-cell lung cancer: a phase II trial.
October 2006, Cancer chemotherapy and pharmacology,
R M Scher, and R Kosierowski, and C Lusch, and R Alexander, and S Fox, and I Redei, and F Green, and B Raskay, and K Amfoh, and P F Engstrom, and P J O'Dwyer
Trimetrexate in locally advanced or metastatic adenocarcinoma of the pancreas. A phase II study of the Northern California Oncology Group.
November 1990, Investigational new drugs,
R M Scher, and R Kosierowski, and C Lusch, and R Alexander, and S Fox, and I Redei, and F Green, and B Raskay, and K Amfoh, and P F Engstrom, and P J O'Dwyer
Gemcitabine plus celecoxib in patients with advanced or metastatic pancreatic adenocarcinoma: results of a phase II trial.
April 2008, American journal of clinical oncology,
R M Scher, and R Kosierowski, and C Lusch, and R Alexander, and S Fox, and I Redei, and F Green, and B Raskay, and K Amfoh, and P F Engstrom, and P J O'Dwyer
Phase II study of epirubicin in advanced adenocarcinoma of the pancreas.
February 1985, European journal of cancer & clinical oncology,
R M Scher, and R Kosierowski, and C Lusch, and R Alexander, and S Fox, and I Redei, and F Green, and B Raskay, and K Amfoh, and P F Engstrom, and P J O'Dwyer
Randomised phase II trial of gemcitabine and nab-paclitaxel with necuparanib or placebo in untreated metastatic pancreas ductal adenocarcinoma.
June 2020, European journal of cancer (Oxford, England : 1990),
R M Scher, and R Kosierowski, and C Lusch, and R Alexander, and S Fox, and I Redei, and F Green, and B Raskay, and K Amfoh, and P F Engstrom, and P J O'Dwyer
Phase II trial of topotecan in patients with advanced renal cell carcinoma.
January 1994, Investigational new drugs,
R M Scher, and R Kosierowski, and C Lusch, and R Alexander, and S Fox, and I Redei, and F Green, and B Raskay, and K Amfoh, and P F Engstrom, and P J O'Dwyer
Phase II study of 4'-deoxydoxorubicin (esorubicin) in advanced or metastatic adenocarcinoma of the stomach.
February 1991, Investigational new drugs,
R M Scher, and R Kosierowski, and C Lusch, and R Alexander, and S Fox, and I Redei, and F Green, and B Raskay, and K Amfoh, and P F Engstrom, and P J O'Dwyer
Phase II trial of piroxantrone in metastatic gastric adenocarcinoma.
January 1994, Investigational new drugs,
Copied contents to your clipboard!